CC
MRNA icon

Casdin Capital’s Moderna MRNA Stock Holding History

Casdin Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-175,000
Closed -$7.28M – 47
2024
Q4 		$7.28M Buy
+175,000
New +$8.36M 0.48% 24
2023
Q1 		– Sell
-30,000
Closed -$5.39M – 45
2022
Q4 		$5.39M Buy
+30,000
New +$4.91M 0.42% 34

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Casdin Capital's MRNA Position: Q2 2026 in Review

Casdin Capital held its Moderna (MRNA) position steady in Q2 2026 at 75,000 shares worth $5.25M. The position accounts for 0.26% of the portfolio, ranked #32.

Casdin Capital first reported a position in MRNA in Q3 2022 and has held it in 6 quarters since. The position peaked at $10.8M in Q4 2022. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Casdin Capital held 75,000 shares of Moderna worth $5.25M as of Q2 2026.
  • Casdin Capital left its Moderna share count unchanged in Q2 2026.
  • Moderna made up 0.26% of Casdin Capital's portfolio in Q2 2026, its #32 holding.
  • Casdin Capital first reported a position in Moderna in Q3 2022 and has held it in 6 quarters since.
  • Casdin Capital's Moderna position peaked at $10.8M in Q4 2022.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.